Report Detail
Global Neurostimulation Devices Market
The large and burgeoning global market for implantable neurostimulation devices is approaching nearly $4 billion worldwide. Despite lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of innovative startups and leading medical device companies. The market is expected to maintain high single-digit growth (under 10%) over the next half-decade, expanding by nearly $2 billion by 2020. A major reason for such optimism is not only the sustained and expanding clinical and commercial success of neurostimulation technologies, but also the ongoing, increasing need for safer and more effective treatments to effectively manage the debilitating, chronic symptoms of many incurable diseases/disorders that negatively affect the quality of life in millions of people worldwide.
Implantable neurostimulation (also commonly termed “neuromodulation”) systems, the focus of this report, typically consist of three implantable components (the extension, lead, and battery/power source) and two external components (the control magnet and a handheld programmer). The extension is used to connect the lead to the power source, and the lead is used to deliver the electrical stimulation to the targeted nerve(s). Neurostimulators may be temporary or permanent, depending on their indication, and are limited by their battery life. Long-life batteries are either self-contained or attached percutaneously on the outside of the body. Some batteries are rechargeable, while others must be replaced periodically.
Neurostimulation implant procedures are minimally invasive, reversible, and have demonstrated substantial success in carefully selected patient populations. Neurostimulation systems have gained credibility in treating intractable chronic pain and other debilitating diseases/disorders, such as drug-refractory epilepsy and Parkinson’s disease, and are expected to achieve even greater acceptance over the next decade due to their ability to provide significant relief to no-option patients who have failed standard medication or more conservative treatment.
This dynamic, new report from Meddevicetracker profiles literally dozens of neurostimulation/neuromodulation devices and emerging technologies covering more than 20 treatment areas. A comprehensive market analysis is provided, including 5-year market forecasts (from 2015-2020) by region (US vs. ROW) and by 6 core therapy segments (deep brain stimulation (DBS), gastric nerve stimulation (GNS), spinal cord stimulation (SCS), sacral nerve stimulation (SNS), vagus nerve stimulation (VNS) and cochlear implants. Market analysis also includes market drivers/limiters, trends, and an in-depth competitive analysis, including 2015 market share by supplier (Global/US/ROW) and detailed corporate strategies for lead competitors.